Bayer vs Cipla: Attempting "Patent Linkage" In India
The writ petition filed by Bayer against the Union of India (UOI) and Cipla came up for hearing on the 17th, 18th and then the 25th of February. For those not familiar with this story, please see our previous post. In essence, Bayer filed a writ against the UOI, praying that the DCGI (Drug Controller General of India) be restrained from granting any drug approval to Cipla’s generic version of their patented drug, Sorefanib (sold as “Nexavar”). The key ground […]
Bayer vs Cipla: Attempting "Patent Linkage" In India Read More »

